Supriya Lifescience Limited reported an 11.3% year-on-year increase in net profit to ₹2,091.2 million for the year ended March 31, 2026, driven by robust revenue growth and operational efficiency. Revenue from operations rose 18.9% to ₹8,278.7 million, while EBITDA grew 12.8% to ₹2,940.5 million. For the quarter ended March 31, 2026, net profit surged 47.4% to ₹742.3 million, and revenue increased 50.2% to ₹2,765.3 million. The Board of Directors recommended a final dividend of Re. 1.00 per equity share, subject to shareholder approval.

FY26 Financial Performance

The company recorded growth across key financial metrics for the full year. The following table summarises the audited results for FY26 compared to FY25:

Q4 Performance

In the fourth quarter of FY26, the company reported a net profit of ₹742.3 million, compared to ₹503.7 million in Q4FY25. Revenue for Q4FY26 was ₹2,765.3 million, up from ₹1,841.1 million in the corresponding period of the previous year. EBITDA for the quarter stood at ₹976.2 million with a margin of 35.3%, compared to a margin of 36.7% in the prior year. Profit before tax (PBT) for the quarter increased 43.8% to ₹921.3 million.

Segment and Operational Details

The anesthetic segment continued to be the primary growth driver during FY26, contributing 54% of total revenues compared to 49% in FY25, while the vitamins segment contribution increased to 12% from 11%. Europe remained the largest market, contributing 40% of FY26 revenues, followed by Asia at 33% and LATAM at 20%. Export contribution remained strong at approximately 82% of FY26 revenues.

Capacity utilisation improved to 74% in FY26 from 70% in FY25, supported by the ramp-up of Module E at the Lote facility. The company commercialised its Liquid Anesthetic product and witnessed encouraging traction in newly launched products across the cardiovascular and ADHD segments. The Ambernath formulation facility commissioned five finished dosage manufacturing lines and continues to progress on validation and dossier submission activities.

Dividend Declaration

The Board of Directors, at its meeting held on May 27, 2026, recommended a final dividend of Re. 1.00 per equity share, equivalent to 50% on the face value of ₹2 each. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

Management Commentary and Outlook

During the earnings call held on May 28, 2026, management highlighted that the Lote facility received a USFDA Establishment Inspection Report (EIR) with a Voluntary Action Indicated classification following a surprise inspection in February 2026. The company reiterated its guidance for FY27, targeting approximately 20% annual revenue growth and EBITDA margins between 33% and 35%. Management stated the trajectory towards the ₹1,000 crore revenue milestone by FY27 remains on track, underpinned by a robust pipeline and planned launches of 3 to 4 products annually. The company secured all clearances for the Patalganga land, with Phase 1 groundbreaking expected in FY27 and a total capex of around ₹200 crore earmarked for the facility.

Supriya Lifescience has set an ambitious revenue milestone, targeting over ₹1000 crore by FY27. This target reflects the pharmaceutical company's strategic intent to significantly scale its business operations in the coming years.

Revenue Target Overview

The company has outlined a clear financial goal as part of its growth roadmap. The key target is summarized below:

This milestone represents a significant ambition for Supriya Lifescience as it looks to strengthen its position in the pharmaceutical industry.